Abbott Laboratories (ABT)

NYSE: ABT · USD

$108

-0.15 (-0.1%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-08-09 02:00 UTC. Latest published research analyzed 2026-05-09 · historical · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh ABT analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-09

Our latest published analysis: ABT rated Strong Buy

ABT is rated Strong Buy at $84.32 versus the reconciled fair value midpoint of $107.02, implying +26.92% upside/downside. Confidence is separately disclosed at 88/100.

Fair value (mid)

$107 / share

$87.2 – $127

Upside to FV

+26.9%

from $108

Confidence

88/100

Moat

9/10

Read full analysis

Market cap	$146.9B
Revenue (ttm)	46.6B
Net income (ttm)	5.4B
EPS (ttm)	$3.09
Shares out	1.7B
P/E (trailing)	34.9x
P/E (forward)	13.9x
Dividend	$2.52 (2.34%)
Volume	6,606,576
Beta	0.58
Price target	$118	+9.8%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 46.6B
Net income (ttm): 5.4B
EPS (ttm): $3.09
P/E (trailing): 34.9x
P/E (forward): 13.9x
Market cap: $146.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$43.08B	$43.65B	$40.11B	$41.95B	$44.33B	+0.7%
Gross profit	$24.54B	$24.51B	$22.13B	$23.24B	$25.01B	+0.5%
Operating income	$8.43B	$8.36B	$6.48B	$6.83B	$8.05B	-1.1%
Net income	$7.07B	$6.93B	$5.72B	$13.40B	$6.52B	-2.0%
EPS (diluted)	—	$3.91	$3.26	$7.64	$3.72	-1.2%
EBITDA	$12.28B	$12.13B	$10.54B	$10.79B	$12.08B	-0.4%
R&D	$2.74B	$2.89B	$2.74B	$2.84B	$2.94B	+1.8%
SG&A	$11.32B	$11.25B	$10.95B	$11.70B	$12.33B	+2.2%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	434.8B	69.5x	6.8x	17.7%	+3.7%	+29.2%	Hold
ACN	Accenture plc	107.5B	14.1x	1.5x	27.1%	+8.8%	-26.7%	Buy
ADI	Analog Devices Inc.	189.9B	58.1x	14.9x	9.1%	+15.5%	+79.1%	Sell
AMGN	Amgen Inc.	222.2B	25.5x	5.8x	19.8%	+8.4%	+48.7%	Strong Buy
BIIB	Biogen Inc.	30.7B	36.9x	3.1x	8.9%	-3.0%	+60.8%	Strong Buy
BMY	Bristol-Myers Squibb Company	132.2B	14.2x	2.7x	21.7%	+2.1%	+51.3%	Strong Buy

All ABT indicators

Market & fundamental data

Available fields

291

Groups with data

Currency

USD

Showing 291 of 291 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000001800
Company name	Abbott Laboratories
Country	United States
Country code	US
Cusip	002824100
Employees	115,000
Employees Change	1,000%
Employees Change Percent	0.88
Enterprise value	$213.7B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
In Index	SP500
Industry	Medical Devices
Industry PE	38.73
Industry PE Fwd	19.89
Isin	US0028241000
Last refreshed	2026-08-09
Market cap	$186.6B
Market cap category	Large-Cap
Price	$108
Price currency	USD
Rev Per Employee	405,086.96x
Sector	Healthcare
Sector PE	49.71
Sector PE Fwd	22.46
Sic	2834
Symbol	ABT
Website	https://www.abbott.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.9%
EV Earnings	39.56x
EV Sales Forward	4.05x
EV/EBIT	29.09x
EV/EBITDA	19.8x
EV/FCF	27.31x
EV/Sales	4.59x
FCF yield	4.19%
Forward P/E	18.59x
P/B ratio	3.65x
P/E ratio	34.88x
P/S ratio	4x
PE Ratio10 Y	50.43x
PE Ratio3 Y	27.09x
PE Ratio5 Y	27.72x
PEG ratio	2.16x
PS Forward	3.53x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	15.77%
EBITDA Margin	23.17%
FCF margin	16.8%
Gross margin	56.85%
Gross Profit	$26.5B
Gross Profit Growth	9.39%
Gross Profit Growth Q	15.59%
Gross Profit Growth3 Y	5.98%
Gross Profit Growth5 Y	2.79%
Net Income	$5.4B
Net Income Growth	-61.19%
Net Income Growth Q	-47.84%
Net Income Growth Years	0%
Net Income Growth3 Y	1.66%
Net Income Growth5 Y	-3.18%
Pretax Margin	16.12%
Profit Margin	11.65%
Profit Per Employee	$46,965
Profitable Quarters	$34
Profitable Years	35
ROA	5.33
Roa5y	6.84
ROCE	8.04
ROE	10.58
Roe5y	19.7
ROIC	7.51
Roic5y	14.92

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	11.14%
Cagr15y	12.81%
Cagr1y	-15.76%
Cagr20y	10.63%
Cagr3y	2.15%
Cagr5y	-0.55%
Div CAGR10	9.29%
Div CAGR3	7.43%
Div CAGR5	7.72%
EPS Growth	-61.23
EPS Growth Q	-47.53
EPS Growth Years	0
EPS Growth3 Y	1.84
EPS Growth5 Y	-2.73
FCF Growth	15.48%
FCF Growth Q	28.87%
FCF Growth3 Y	12.55%
FCF Growth5 Y	-1.97%
OCF Growth	9.61%
OCF Growth Q	21.54%
OCF Growth10 Y	13.31%
OCF Growth3 Y	9.95%
OCF Growth5 Y	-1.4%
Revenue Growth	8.06x
Revenue Growth Q	13.02x
Revenue Growth Quarters	11x
Revenue Growth Years	2x
Revenue Growth3 Y	5.01x
Revenue Growth5 Y	2.98x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.48
Assets	$109.2B
Cash	$5.6B
Current Assets	$24.5B
Current Liabilities	$17.8B
Debt	$32.7B
Debt EBITDA	$3.03
Debt Equity	$0.63
Debt FCF	$4.18
Equity	$51.8B
Interest Coverage	9.59
Liabilities	$57.5B
Long Term Assets	$84.7B
Long Term Liabilities	$39.6B
Net Cash	$-27.1B
Net Cash By Market Cap	$-14.54
Net Debt EBITDA	$2.51
Net Debt Equity	$0.52
Net Debt FCF	$3.47
Tangible Book Value	$-1.3B
Tangible Book Value Per Share	$-0.78
WACC	6.59

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.38
Inventory Turnover	2.82
Net Working Capital	$4.1B
Quick ratio	0.8
Working Capital	$6.7B
Working Capital Turnover	$5.25

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.08%
Dividend Growth	6.9%
Dividend Growth Years	54%
Dividend per share	$2.52
Dividend Years	56
Dividend Yield	2.34%
Ex Div Date	2026-07-15
Last Dividend	$0.63
Payout Frequency	Quarterly
Payout Ratio	81.54%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	187.54%
1Y total return	-15.76%
200-day SMA	107.8
3Y total return	6.6%
50-day SMA	95.27
50-day SMA vs 200-day SMA	50under200
5Y total return	-2.74%
All Time High	142.6
All Time High Change	-24.4%
All Time High Date	2021-12-27
All Time Low	0.24
All Time Low Change	45,141.29%
All Time Low Date	1974-10-04
ATR	2.92
Beta	0.58
Beta1y	-0.34
Beta2y	0.14
Ch YTD	-13.95
High	108
High52	137.5
High52 Date	2025-09-22
High52ch	-21.59%
Low	106
Low52	81.97
Low52 Date	2026-05-11
Low52ch	31.52%
Ma50ch	13.17%
Premarket Change Percent	-0.47
Premarket Price	$107
Premarket Volume	1,933
Price vs 200-day SMA	0.03%
RSI	67.41
RSI Monthly	47.53
RSI Weekly	56.66
Sharpe ratio	-0.67x
Sortino ratio	-0.73
Total Return	2.42%
Tr YTD	-12.35
Tr15y	510.04%
Tr1m	13.54%
Tr1w	2%
Tr3m	25.82%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	27
Analyst Count Top	6
Analyst Price Target Top	$116
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$1.28
Earnings EPS Estimate Growth	1.59
Earnings Revenue Estimate	12,509,910,264x
Earnings Revenue Estimate Growth	12.28x
Operating Income	$8.2B
Operating Income Growth	0.33
Operating Income Growth Q	-15.74
Operating Income Growth3 Y	5.94
Operating Income Growth5 Y	-0.08
Operating margin	17.68
Price target	$118
Price Target Change	$9.84
Price Target Change Top	$7.6

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,697,487,009%
Float Percent	98.1%
Net Borrowing	16,538,000,000
Shares Insiders	0.49%
Shares Institutions	80.23%
Shares Out	1,730,383,296
Shares Qo Q	-0.23%
Shares Yo Y	-0.08%
Short Float	1.46%
Short Ratio	1.83
Short Shares	1.44

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$7.1B
Adjusted OCF	9,187,000,000
Average Volume	11,900,649.25x
Bv Per Share	29.54
CAPEX	$-2.1B
Ch10y	138.2
Ch15y	114.6
Ch1m	12.74
Ch1w	2
Ch1y	-17.66
Ch20y	128.2
Ch3m	24.93
Ch3y	0.15
Ch5y	-11.75
Ch6m	-2.72
Change	-0.14%
Change From Open	0.73
Close	108
Days Gap	-0.86
Depreciation Amortization	3,446,000,000
Dollar Volume	712,254,958.6
Earnings Date	2026-07-16
Earnings Time	bmo
EBIT	$7.3B
EBITDA	$10.8B
EPS	$3.09
F Score	5
FCF	$7.8B
FCF EV Yield	3.66x
FCF Per Share	$4.52
Financing CF	10,638,000,000
Fiscal Year End	December
Founded	1,888
Goodwill	35,244,000,000
Graham Number	45.32015
Graham Upside	-57.96
Income Tax	$2.1B
Investing CF	-22,367,000,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-16
Last Report Date	2026-06-30
Last Split Date	1998-06-01
Last Split Type	Forward
Last10k Filing Date	2026-02-20
Lynch Fair Value	$15.45
Lynch Upside	-85.67
Ma150	101.7
Ma150ch	6.04%
Ma20	102
Ma20ch	5.66%
Net CF	-1,847,000,000
Next Earnings Date	2026-10-14
Open	107
Optionable	Yes
P FCF Ratio	23.84
P FCF Ratio SBC	26.25
P OCF Ratio	18.83
P OCF Ratio SBC	20.31
Payment Date	2026-08-17
Position In Range	91.84
Post Close	107.8
Postmarket Change Percent	-0.14
Postmarket Price	$108
Ppne	12,812,000,000
Pre Close	108
Price Date	2026-08-07
Price EBITDA	$17.29
Relative Volume	0.56x
Revenue	46,585,000,000x
SBC By Revenue	1.54x
Share Based Comp	718,000,000
Tax By Revenue	4.48x
Tax Rate	27.77%
Tr20y	653.5%
Tr6m	-1.42%
Us State	Illinois
Views	159
Volume	6,606,576
Z Score	3.49

Frequently asked questions

About this ABT report

What is the latest published ABT stock rating?

Abbott Laboratories is shown with strong buy in the latest published report, analyzed 2026-05-09. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ABT analysis?

The full latest published report, analyzed 2026-05-09, lives at /stocks/ABT/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for ABT?

The latest published report analyzed 2026-05-09 frames ABT around USD 87 to USD 127. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the ABT page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-09). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Abbott Laboratories (ABT)

Coverage state: Latest published research available

Generate a fresh ABT analysis

Our latest published analysis: ABT rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · ABT

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All ABT indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ABT

Frequently asked questions